Product image of Menago (Irbesartan) supplied by GNH India

Menago

Active Ingredient:
Irbesartan
Origin:
EU

Menago (Irbesartan)

Irbesartan, the active ingredient in Menago, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetic nephropathy in adult patients.

GNH India supplies Menago as a licensed, GDP‑compliant international pharmaceutical product, adhering to European Union manufacturing standards. The company provides the medication to hospitals, pharmacies and clinics worldwide, supporting consistent quality, regulatory compliance and reliable supply chains for cardiovascular care.

Manufacturer / TM Owner

Adelco Chromatourgia Athinon E Colocotronis Bros Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Irbesartan is used to treat conditions related to the renin‑angiotensin system and to protect renal function.

  • Hypertension: lowers elevated blood pressure, reducing the risk of cardiovascular events.
  • Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.
  • Left ventricular hypertrophy: helps reduce the risk of stroke in hypertensive patients with cardiac remodeling.

How It Works

  • Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal cells, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This inhibition leads to vasodilation, reduced sodium and water retention, and ultimately lower systemic blood pressure while offering renal protective effects.

Side Effects

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Dizziness: sensation of light‑headedness, especially after standing.
  • Fatigue: feeling unusually tired or weak.
  • Headache: mild to moderate cranial pain.
  • Hyperkalemia: elevated blood potassium levels.
  • Abdominal pain: discomfort in the stomach area.
  • Cough: occasional dry throat irritation.

Serious or Rare Side Effects

  • Angioedema: swelling of the face, lips, tongue or throat.
  • Severe hyperkalemia: dangerously high potassium that may affect heart rhythm.
  • Acute renal failure: sudden loss of kidney function.
  • Hepatic injury: liver enzyme elevations or hepatitis.
  • Neutropenia: marked reduction in white blood cells.
  • Anaphylaxis: life‑threatening allergic reaction.

Precautions & Warnings

Before initiating Irbesartan therapy, consider the following precautions.

  • Blood pressure monitoring: regularly check to ensure therapeutic control.
  • Renal function assessment: evaluate serum creatinine and eGFR before and during treatment.
  • Electrolyte surveillance: monitor potassium levels, especially with concomitant potassium‑sparing agents.
  • Hypersensitivity: avoid in patients with known ARB allergy.
  • Pregnancy and lactation: contraindicated in the second and third trimesters; consult a specialist.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Irbesartan can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid)

  • Aliskiren (in diabetic patients): combined use may increase renal dysfunction and hyperkalemia.
  • Potassium‑sparing diuretics or supplements: risk of severe hyperkalemia.
  • ACE inhibitors: concurrent use can lead to additive hypotension and renal impairment.

Moderate Interactions (Monitor Closely)

  • Thiazide diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring.
  • NSAIDs: can reduce renal clearance of irbesartan and raise potassium.
  • CYP3A4 inhibitors (e.g., ketoconazole): may increase irbesartan plasma concentrations.
  • Rifampin: may lower irbesartan levels, reducing efficacy.
  • Lithium: increased lithium concentrations, risking toxicity.

Frequently Asked Questions

Menago contains irbesartan, an angiotensin II receptor blocker indicated for the treatment of hypertension and for slowing the progression of diabetic nephropathy in adults. It helps lower high blood pressure and protects kidney function in patients with type 2 diabetes.

Irbesartan selectively blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. This results in relaxed blood vessels, reduced sodium and water retention, and lower systemic blood pressure, while also offering renal protective effects.

The appropriate dose of Menago is determined by a qualified prescriber based on the individual’s medical condition, response to therapy, and other medications. Patients should follow the dosing instructions provided by their healthcare professional.

Irbesartan is generally contraindicated during the second and third trimesters of pregnancy because it may harm the developing fetus. Safety during breastfeeding has not been established, so a healthcare provider should be consulted before use.

To request Menago, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with ACE inhibitors, irbesartan (Menago) offers similar blood‑pressure control but a lower incidence of cough and angio‑edema. Within the ARB class, its efficacy and safety profile are comparable to agents such as losartan and valsartan, with choice often guided by patient tolerance and cost.

Menago should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat and direct sunlight to maintain stability and potency throughout its shelf life.

Menago is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include angio‑edema, severe hyperkalemia, acute renal failure, and significant liver injury. Patients should seek immediate medical attention if they experience swelling of the face or throat, rapid weight gain, muscle weakness, or yellowing of the skin or eyes.

Menago should be avoided in individuals with known hypersensitivity to irbesartan or other ARBs, in patients with severe hepatic impairment, and in pregnant women during the second and third trimesters. Caution is also advised for those with unstable kidney function or high potassium levels.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Irbesartan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT